Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes.
2003
The in vitro metabolism of tolperisone, 1-(4-methyl-phenyl)-2-methyl-3-(1-piperidino)-1-propanone-hydrochloride, a centrally acting muscle relaxant, was examined in human liver microsomes (HLM) and recombinant enzymes. Liquid chromatography-mass spectrometry measurements revealed methyl-hydroxylation (metabolite at m/z 261; M1) as the main metabolic route in HLM, however, metabolites of two mass units greater than the parent compound and the hydroxy-metabolite were also detected ( m/z 247 and m/z 263, respectively). The latter was identified as carbonyl-reduced M1, the former was assumed to be the carbonyl-reduced parent compound. Isoform-specific cytochrome P450 (P450) inhibitors, inhibitory antibodies, and experiments with recombinant P450s pointed to CYP2D6 as the prominent enzyme in tolperisone metabolism. CYP2C19, CYP2B6, and CYP1A2 are also involved to a smaller extent. Hydroxymethyl-tolperisone formation was mediated by CYP2D6, CYP2C19, CYP1A2, but not by CYP2B6. Tolperisone competitively inhibited dextromethorphan O -demethylation and bufuralol hydroxylation ( K i = 17 and 30 μM, respectively). Tolperisone inhibited methyl p -tolyl sulfide oxidation ( K i = 1200 μM) in recombinant flavin-containing monooxygenase 3 (FMO3) and resulted in a 3-fold ( p
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
30
References
28
Citations
NaN
KQI